CA-DEBIOPHARM
9.1.2024 15:01:34 CET | Business Wire | Press release
MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner. The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
“We see significant synergies between MedaSystems and Debiopharm Innovation Fund. Our mutual dedication to building new approaches to pharmaceutical drug development and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably. This funding supports our goal of making life-saving treatments more easily available to patients and physicians while advancing research and development of new therapies,” said Fiona Smythe, CEO of MedaSystems.
MedaSystems' SaaS platform facilitates the rapid processing of treatment inquiries and introduces new data capture capabilities, streamlining treatment for patients with unmet medical needs and aiding in collecting real-world data (RWD) for regulatory submissions. The platform is a vital link that ensures smooth collaboration among key partners in situations requiring pre-approval access. Physicians can swiftly manage patient requests and oversee the entire process in-app, working seamlessly with their teams and pharmacists. Pharmaceutical companies can integrate external partners like contract research organizations (CROs), guaranteeing effective communication, integrated services, and the quick shipment of treatment.
"Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions. Our investment in MedaSystems aligns perfectly with our dedication to innovation and the power of digital health technology in transforming patient outcomes. We believe their visionary approach to simplifying pre-approval access will play a key role in accelerating the delivery of life-saving treatments around the world. Together, we look forward to crafting a future where every patient has timely access to the most promising therapies." said Vincent Lepreux, Investment Principal at Debiopharm Innovation Fund.
About MedaSystems
MedaSystems is the leading developer of software that streamlines the handling of requests for experimental therapies from healthcare providers, supporting both Expanded Access and Post-Trial Access. MedaSystems' secure and GxP compliant application acts as a centralized environment, connecting physicians and pharmaceutical companies to facilitate global patient access to investigational therapies. By enabling the tracking and management of inquiries and data collection from these programs, MedaSystems transforms communications with clinicians into true partnerships, significantly reducing time and frustration for both parties involved.
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017, Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As of September 2023, Debiopharm Innovation Fund is expanding its footprint through a new Seed financing activity.
For more information, please visit www.debiopharm.com/innovation-fund/
To learn more about investment criteria visit https://www.debiopharm.com/innovation-fund/approach/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109101056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
58% of Consumers Say They Don't Care Whether a Product is a National Brand or Private Label. They Just Buy What They Need21.8.2026 12:00:00 CEST | Press release
New NIQ & World Data Lab report reveals how consumer polarization is redefining value, accelerating private label adoption, and reshaping competition on the shelf As fast-moving consumer goods (FMCG) prices rose 26% globally between 2021 and 2025, consumers have become more deliberate about where they save and where they spend. NielsenIQ (NYSE: NIQ) has released new findings showing that private label is no longer viewed simply as a lower-cost substitute, but as a credible competitor across value, mainstream, and premium segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819950224/en/ Private label is no longer just a value play. The findings, published in NIQ’s latest report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, created in collaboration with World Data Lab, show how consumer polarization is redefining value and reshaping competition on the shelf. The report also draws on ins
Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 21:10:00 CEST | Press release
Company to focus on deepening its Autonomous IT capabilities, further expanding AI offerings across its portfolio, and strengthening customer and partner engagement Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build
PCI Energy Solutions to Join Mitsubishi Electric, Reinforcing Long-Term Commitment to Customers, Employees, and the Energy Industry20.8.2026 19:46:00 CEST | Press release
Mitsubishi Electric to retain PCI’s core management team and support continuity of operations, customer service, and product innovation PCI Energy Solutions ("PCI"), a leading U.S.-based provider of enterprise software for energy management and optimization, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi Electric Corporation. The agreement was executed on August 20, 2026 (Japan Standard Time). The Transaction represents a strong endorsement of PCI's business, technology, employees, customer relationships and position in the energy industry. Mitsubishi Electric intends to retain PCI's core management team following completion of the Transaction, enabling PCI to preserve leadership continuity, industry expertise and its customer-focused operating model while benefiting from Mitsubishi Electric's global scale, complementary capabilities and long-term investment capacity. The agreement has been signed, but the Transaction has not yet closed. PC
Perma-Pipe Secures More Than $67 Million in New Orders in the Second Quarter of 202620.8.2026 19:02:00 CEST | Press release
Awards include significant Oil & Gas projects in MENA and Canada, as well as the Company's largest single leak detection project to date and continued growth at its new Ohio facility. Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH), a global leader in engineered piping and corrosion protection solutions, today announced that the Company secured more than $67 million in new orders during the second quarter of fiscal 2026, representing strong demand across its strategically important end-markets and geographies. The orders further strengthen Perma-Pipe's backlog and provide increased visibility into future revenue growth. The Company's backlog remains well diversified across geographies, customers and end-markets. The Company continued to see strong demand across its core Oil & Gas and infrastructure markets, while also securing important new business in emerging applications, including advanced leak detection and monitoring solutions. During the quarter, Perma-Pipe secured sizabl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom